Medindia2d
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
Schizophrenic drug user, 23, who stabbed his mother to death outside their £1m home after becoming convinced she was an alien is given a life sentence
Schizophrenic drug user, Gregor Bauld, who stabbed his mother to death outside their £1m home after becoming convinced she ...
Santa Rosa Press Democrat4d
Sonoma County prepares to launch CARE Court, supervisors allocate initial funding
Sonoma County is among 50 counties due to implement CARE Court by Dec. 1. The program is meant to address the state’s most ...
The Pharma Letter6d
Positive Phase III results for Intra-Cellular’s Caplyta in schizophrenia
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...
Medpage Today on MSN6d
Long-Term Data Support Efficacy, Safety of New Schizophrenia Drug
Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with ...